Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FC versus FC + alemtuzumab in previously untreated high-risk CLL
NL-OMON25345Phase 3Not yet recruiting
- Sponsor
- Rigshospitalet
- Start
- Dec 2005
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of fludarabine, cyclophosphamide and alemtuzumab in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) (2 arms), sponsored by Rigshospitalet. Primary endpoint: Progression-free survival. Planned start Dec 2005; status: not yet recruiting.
02
Drugs
fludarabinecyclophosphamidealemtuzumab
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on NL-OMON25345.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON25345.